

recombination system for chromosome engineering in *Escherichia coli*," P.N.A.S. 97(11):5978-5983 (2000).

Simian-Human HAV Chimeras Encoding a Hepatitis A Virus Having a Chimeric 2C Protein

G Raychaudhuri, SU Emerson, RH Purcell (NIAID)

Serial No. 60/015,642 filed 19 Apr 1996; PCT/US97/06506 filed 18 Apr 1997; Serial No. 09/171,387 filed 24 Mar 1999

Licensing Contact: Carol Salata, 301/496-7735 ext. 232; e-mail: salatac@od.nih.gov.

The claimed invention provides nucleic acid sequences which encode hepatitis A viruses having a chimeric 2C protein. The chimeric 2C gene consists of sequences from both the human strain and the simian AGM-27 strain. The chimeric virus is a promising candidate for an attenuated hepatitis A virus vaccine which may be more economical than an inactivated vaccine, especially in underdeveloped countries where hepatitis A is endemic. Additional information on the chimeras may be found in Raychaudhuri et al., "Utilization of chimeras between human(HM175) and simian(AGM27) strains of hepatitis A virus to study the molecular basis of virulence," J. Virol. 72:7467-7474(1998).

Novel Antimalarial Compounds, Methods of Synthesis Thereof, Pharmaceutical Compositions Comprising Same, and Methods of Using Same for Treatment and Prevention of Malaria

Michael R. Boyd (NCI), Gerhard Bringmann (EM), Sven Harmsen (EM), Roland Gotz (EM), T. Ross Kelly (EM), Matthias Wenzel (EM), Guido Francois (EM), J. D. Phillipson (EM), Laurent A. Assi (EM), Christopher Schneider (EM) Serial No. 08/195,547, filed 02/14/1994, now U.S. Patent 5,639,761; Serial No. 08/843,582, filed 04/16/1997; Serial No. 08/279,261, filed 07/22/1994, now U.S. Patent 5,552,550; Serial No. 08/674,362, filed 07/01/1996, now U.S. Patent 5,763,613; Serial No. 09/001,801, filed 12/31/1997, now U.S. Patent 6,140,339; Serial No. 09/527,002, filed 03/16/2000; Serial No. 08/279,339, filed 07/22/1994, now U.S. Patent 5,571,919; Serial No. 08/363,684, filed 12/23/1994, now U.S. Patent 5,578,729; Serial No. 08/674,359, filed 07/01/1996, now U.S. Patent 5,789,594; Serial No. 08/721,084, filed 09/24/1996, now U.S. Patent 5,786,482

Licensing Contact: Peter Soukas; 301/496-7056 ext. 268; e-mail: soukasp@od.nih.gov.

According to data recently reported by the World Health Organization (WHO), the death rate from malaria exceeds one million individuals per year. The Public Health Service seeks exclusive or non-exclusive licensee(s) to develop and commercialize the technology claimed within the portfolio of U.S. patents issued and pending, and corresponding international patents issued and pending. These patents and pending applications claim an exceptionally broad universe of novel naphthylisoquinoline alkaloid compounds, and methods of total synthesis thereof. Representative examples of these compounds have been shown to have potent in vitro activity against malaria parasites, including parasites that are highly resistant to available antimalarial drugs. Representative examples have also been shown to have potent in vivo activity against malaria parasites in animal models. Pharmaceutical compositions comprising these compounds, as well as methods of using the compounds to treat or prevent a malarial infection of a host, are claimed. The relative structural simplicity of this class of compounds, and the ready synthetic access thereto, provide unprecedented opportunities for structure-activity relationship (SAR), lead-optimization and antimalarial drug development. The technology is further described in the following publications: J. Nat Prod. 1997 Jul.;60(7):677-83 and Bioorg. Med. Chem. Lett. 1998 Jul.;8(13): 1729-34.

Dated: February 2, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 01-3605 Filed 2-12-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of

federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

The ImmunoChip

Matthias Lorenz (NCI)
DHHS Reference No. E-288-00/0 filed 29 Dec 2000

Licensing Contact: Richard Rodriguez; 301/496-7056 ext. 287; e-mail: rodrigur@od.nih.gov.

The inventors have established a method to select sequences from databases for the construction of custom microarrays. Using this method, an immunological relevant microarray (ImmunoChip) was constructed. The ImmunoChip is a cDNA microarray which contains more than 13,000 different murine immunological-relevant genetic probes. The ImmunoChip can be used to study gene expression of immune cells or immune infiltrating tissues and organs. Specifically, the chip could be used for immunologically related research and/or vaccine development for a variety of human diseases which would include, but not necessarily limited to, cancer, infectious diseases, autoimmune diseases and allergies.

Water Soluble Amino Acid Analogs of Amino flavone Compounds

Kenneth M. Snader et al. (NCI)
DHHS Reference No. E-279-99/0 filed 06 Apr 2000

Licensing Contact: Girish Barua; 301/496-7735 ext. 263; e-mail: baruag@od.nih.gov.

Many potential drugs of cancer chemotherapy intended for parenteral administration have been abandoned because the active ingredient is either slightly soluble or water-insoluble. Various methods have been developed to improve water solubility of these drugs. However, these methods can be complex and have a negative impact resulting from the use of co-solvents and complexing agents. The present invention addresses these problems by providing a method of producing water-

soluble analogues of water-insoluble drugs.

In particular, the present invention describes novel analogues derived from 5-aminoflavone (TK2339) compounds. These derivatives have shown good differential activity in the NCI 60-cell line in vitro cancer drug screen with potent and selective cytotoxicity against CAKI-1 and A498 renal, MCF-7 breast, and OVCAR-5 ovarian carcinoma cell lines. In addition, these derivatives have shown in vivo activity against CAKI-1 and A498 renal carcinoma xenographs.

To overcome poor solubility of many members of the flavone class of compounds, a series of more hydrophilic, polar conjugates were prepared which are capable of forming soluble salts. These novel compounds display improved solubility in aqueous solutions over the parent compound without sacrificing potent antitumor activity. Since these compounds possess very favorable pharmaceutical properties, they have the greater potential to be useful in the treatment of human cancers.

Dated: February 2, 2001.

Jack Spiegel,

Director, Division of Technology, Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 01-3606 Filed 2-12-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 01-33, Review of R13 Grants.

Date: February 16, 2001.

Time: 11 a.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: 45 Center Drive, Natcher Building, Conference Room E1/2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: H. George Hausch, PhD, Chief, 4500 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892, (301) 594-2372.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 01-34, Review of training grants.

Date: February 21-22, 2001.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: The Hyatt Regency Hotel, 100 Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Yujing Liu, MD, PhD, Scientific Review Administrator, National Institute of Dental & Craniofacial Res., 45 Center Drive, Natcher Building, Rm. 4AN44F, Bethesda, MD 20892, (301) 594-2372.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 01-24, Review of R13 Grants.

Date: February 28, 2001.

Time: 10 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: H. George Hausch, PhD, Chief, 4500 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892, (301) 594-2372.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 01-25, Review of R01s.

Date: April 5, 2001.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Yasaman Shirazi, PhD, Scientific Review Administrator, 4500 Center Drive, Natcher Building, Rm. 4AN44F, National Institute of Dental & Craniofacial Res., Bethesda, MD 20892, (301) 594-2372.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 01-28, Review of R44 Grants.

Date: April 6, 2001.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Philip Washko, PhD, DMD, Scientific Review Administrator, 45 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892, (301) 594-2372.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel 01-17, Review of R01 Grants.

Date: April 11, 2001.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Philip Washko, PhD, DMD, Scientific Review Administrator, 45 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892, (301) 594-2372.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel.

Date: April 24, 2001.

Time: 1 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: 45 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Philip Washko, PhD, DMD, Scientific Review Administrator, 45 Center Drive, Natcher Building, Rm. 4AN44F, National Institutes of Health, Bethesda, MD 20892, (301) 594-2372.

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: February 6, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-3593 Filed 2-12-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Dental & Craniofacial Research; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.